Galanin: A Biologically Active Peptide

被引:61
|
作者
Vrontakis, Maria E. [1 ]
机构
[1] Univ Manitoba, Fac Med, Dept Human Anat & Cell Sci, 730 William Ave, Winnipeg, MB R3E OW3, Canada
关键词
Galanin; Galanin Receptors; Nervous System; Alzheimer's; Depression; Pain; Nerve Regeneration; Transgenic; Drug treatment; Therapeutics;
D O I
10.2174/1568007023338914
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Galanin is a biologically active neuropeptide, widely distributed in the central and peripheral nervous systems and the endocrine system. The amino acid sequence of galanin is very conserved (almost 90% among species), indicating the importance of the molecule. Galanin has multiple biological effects. In the central nervous system, galanin alters the release of several neurotransmitters. In particular the ability of galanin to inhibit acetylcholine release, along with the observation of hyperinervation of galanin fibres in the human basal forebrain of Alzheimer's disease patients, suggest a possible role for galanin in the cholinergic dysfunction, characteristic of the disease. Moreover, galanin has been suggested to be involved in other neuronal functions, such as learning and memory, epileptic activity, nociception, spinal reflexes and feeding. Galanin has also been shown to increase the levels of growth hormone, prolactin and luteinizing hormone, to inhibit glucose induced insulin release and to affect gastrointestinal motility. The expression of galanin (mRNA and peptide levels) is elevated following estrogen administration, neuronal activation, denervation and/or nerve injury, as well as during development. The spectrum of galanin's activities indicates that galanin is an important messenger for intercellular communication within the nervous system and the neuroendocrine axis. Galanin acts at specific membrane receptors to exert its effects; so far three human and rodent galanin receptor subtypes have been cloned. Galanin agonists have been shown to have therapeutic application in treatment of chronic pain; galanin antagonists have therapeutic potential in treatment of Alzheimer's disease, depression, and feeding disorders.
引用
收藏
页码:533 / 543
页数:11
相关论文
共 50 条
  • [1] GALANIN - A NOVEL BIOLOGICALLY-ACTIVE PEPTIDE FROM PORCINE INTESTINE
    TATEMOTO, K
    ROKAEUS, A
    JORNVALL, H
    MCDONALD, TJ
    MUTT, V
    FEBS LETTERS, 1983, 164 (01) : 124 - 128
  • [2] GALANIN - A NEWLY ISOLATED BIOLOGICALLY-ACTIVE NEUROPEPTIDE
    ROKAEUS, A
    TRENDS IN NEUROSCIENCES, 1987, 10 (04) : 158 - 164
  • [3] GALANIN - A NOVEL BIOLOGICALLY-ACTIVE GUT PEPTIDE - DISTRIBUTION AND MOLECULAR HETEROGENEITY IN HUMAN AND PIG INTESTINE
    BAUER, FE
    BISHOP, AE
    FERRI, GL
    POLAK, JM
    BLOOM, SR
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 1985, 23 (09): : 407 - 407
  • [4] Database of biologically active peptide sequences
    Dziuba, J
    Minkiewicz, P
    Nalecz, D
    Iwaniak, A
    NAHRUNG-FOOD, 1999, 43 (03): : 190 - 195
  • [5] NEUROTENSIN, A BIOLOGICALLY-ACTIVE PEPTIDE
    BISSETTE, G
    MANBERG, P
    NEMEROFF, CB
    PRANGE, AJ
    LIFE SCIENCES, 1978, 23 (22) : 2173 - 2182
  • [6] BIOLOGICALLY-ACTIVE PEPTIDE ANALOGS OF VASOACTIVE INTESTINAL PEPTIDE
    MUSSO, G
    PATTHI, S
    PROVOW, S
    RYSKAMP, T
    VELICELEBI, G
    REGULATORY PEPTIDES, 1989, 26 (02) : 171 - 171
  • [7] GALANIN - A NEWLY DISCOVERED BIOLOGICALLY-ACTIVE NEUROPEPTIDE OF THE GASTROINTESTINAL-TRACT
    BAUER, FE
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 1990, 28 (03): : 160 - 169
  • [8] Modulation of the biologically active peptides by directed peptide libraries
    Pakkala, M
    Hekim, C
    Huhtala, T
    Häkkinen, M
    Leinonen, J
    Stenman, UH
    Vepsäläinen, J
    Närvänen, A
    BIOPOLYMERS, 2005, 80 (04) : 561 - 561
  • [9] Improvement of transmucosal absorption of biologically active peptide drugs
    Yamamoto, A
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2001, 121 (12): : 929 - 948
  • [10] BIOLOGICALLY-ACTIVE PEPTIDE(S) OF RAT ATRIA
    GHAI, RD
    MANNIELLO, MJ
    GRANAT, F
    ZOGANAS, HC
    GHAI, G
    ROBSON, RD
    GLENN, TM
    FEDERATION PROCEEDINGS, 1984, 43 (03) : 536 - 536